Expansion and Differentiation of Adult Human Pancreas-Derived Progenitor Cells into Functional Islet-Like Organoids

This study establishes a clinically compatible workflow for expanding and differentiating adult human pancreas-derived progenitor cells, specifically CD81+/CD9+ populations isolated from non-endocrine tissue fractions, into functional islet-like organoids capable of glucose-regulated hormone secretion, offering a potential autologous source for diabetes cell replacement therapies.

The Gist

The Big Picture: Turning "Leftovers" into Life-Saving Medicine

Imagine you are baking a massive batch of cookies (the pancreas) to give to a sick friend who needs them (a diabetic patient). Usually, you only pick out the perfect, round cookies (the healthy islet cells) to give them. The rest of the dough, the crumbs, and the broken pieces (the non-endocrine tissue) are thrown away or discarded.

This paper is about a team of scientists who realized that those "crumbs" might actually contain hidden seeds that can grow into new, perfect cookies.

They found a way to take the discarded parts of the pancreas, find the special "seed" cells inside them, and grow them into brand-new, functional insulin factories. This could mean that in the future, a diabetic patient might not need a donor pancreas at all; they could use their own body's "leftovers" to grow a cure.

---

The Step-by-Step Story

1. The Problem: Too Few Donors, Too Many Patients

Currently, the only way to cure some diabetics is to transplant healthy islet cells from a donor. But there aren't enough donors, and the cells often don't last long. It's like trying to fill a swimming pool with a single cup of water. We need a way to make more water.

2. The Discovery: Finding the "Hidden Seeds"

The scientists looked at the tissue that is usually thrown away during the process of harvesting donor islets. They knew from previous work that there are "progenitor cells" (immature stem cells) hiding in there. Think of these as acorns that haven't grown into oak trees yet.

However, finding these acorns in a pile of dirt is hard. So, the team used a special "metal detector" (a machine called a flow cytometer) to find cells with specific tags on their surface: CD81 and CD9.

• The Analogy: Imagine a crowd of people where you need to find only the ones wearing red hats. The scientists used a machine to instantly sort everyone wearing a red hat (CD81+/CD9+) and put them in a separate line.

3. The Growth: From a Single Seed to a Forest

Once they isolated these "red-hat" cells, they put them in a special nutrient soup to let them multiply.

• The Analogy: They took a single acorn and planted it in a greenhouse. Instead of just growing one tree, the acorn multiplied into a whole forest of saplings.
• The Twist: These cells didn't just stay as a flat layer of cells. When crowded together, they naturally curled up into 3D balls (organoids). Think of it like a pile of wet sand that, when pressed, naturally forms a perfect sandcastle tower. These "sandcastles" are the IPC clusters.

4. The Transformation: Waking Up the Factory

The scientists then gave these 3D clusters a specific chemical signal (a drug called ISX9). This was the "wake-up call."

• The Analogy: The clusters were like a factory that was currently empty and silent. The ISX9 was the manager walking in and shouting, "Start the assembly line!"
• The Result: The cells woke up and started building the machinery needed to make insulin and glucagon (the hormones that control blood sugar).

5. The Proof: Do They Work?

The team tested these new "factories" to see if they were real.

• The Test: They turned the lights on and off (simulating eating a meal vs. fasting).
• The Result: When they simulated a high-sugar meal, the new cells pumped out insulin. When they simulated low sugar, they pumped out glucagon. They also reacted to electrical signals just like real human cells do.
• The Verdict: It worked! They had successfully turned "pancreas crumbs" into functional, living insulin factories.

---

Why This Matters (The "So What?")

1. No More Waiting Lists: Right now, people wait years for a donor. This method uses the patient's own tissue (autologous). It's like using your own spare parts to fix your car instead of waiting for a new one to be manufactured.
2. No Rejection: Because the cells come from the patient's own body, the immune system won't attack them. It's like wearing your own skin; it fits perfectly.
3. Waste Not, Want Not: It turns medical waste (the non-endocrine tissue) into a valuable resource.

The Catch (Limitations)

The paper is honest about what they haven't done yet.

• It's Early Days: This is like proving a new engine works on a test track. They haven't put it in a car and driven it across the country (tested in humans long-term) yet.
• Not Perfect: The new cells work well, but they aren't quite as perfect as a brand-new, natural human pancreas yet. They need more time to mature.

The Bottom Line

This research is a major step toward a future where diabetes isn't a life sentence of injections, but a condition we can fix by growing our own replacement parts from the "leftovers" of our own bodies. It turns a dead end into a brand-new road.

Technical Summary

1. Problem Statement

Diabetes mellitus remains a critical global health challenge, and restoring functional pancreatic islet mass is a primary therapeutic goal. While clinical islet transplantation can restore glycemic control, its application is severely limited by:

• Donor scarcity: A shortage of suitable human pancreas donors.
• Variable yields: Inconsistent islet recovery during isolation.
• Graft durability: Limited long-term survival of transplanted islets.
• TPIAT limitations: In Total Pancreatectomy with Islet Autotransplantation (TPIAT), insufficient islet mass recovery often leaves patients insulin-dependent despite technically successful procedures.

Current stem cell-derived islet platforms show promise but require complex differentiation protocols. Conversely, adult pancreatic tissue retains plasticity, but identifying and expanding endocrine-competent progenitor cells from clinically processed, non-endocrine tissue fractions (waste products of islet isolation) has not been fully established for clinical workflows.

2. Methodology

The authors adapted a previously defined Islet Progenitor Cell (IPC) platform to work with non-endocrine pancreatic fractions obtained during real-world clinical islet isolation procedures.

• Source Material: Non-endocrine pancreatic cell fractions were collected during enzymatic digestion and purification steps of TPIAT procedures at Baylor Scott & White Health.
• Expansion & Enrichment:
  • Cells were expanded ex vivo in RPMI media supplemented with N-acetyl cysteine, Trolox, retinoic acid (NTR), and fetal bovine serum (FBS).
  • FACS Sorting: Cells were sorted for surface markers CD81 and CD9, previously identified as IPC markers. Two populations were analyzed: CD81+/CD9+ (enriched) and CD81-/CD9- (depleted).
• Cluster Formation: Sorted cells were expanded into monolayers and then cultured at high density to induce the formation of three-dimensional (3D) IPC clusters.
• Differentiation: Isolated IPC clusters were treated with ISX9 (a small molecule inducer) for 2–14 days to drive endocrine differentiation into islet-like organoids.
• Characterization Techniques:
  • Molecular: RT-qPCR, Single-cell RNA sequencing (scRNA-seq), and immunofluorescence.
  • Functional: Glucose-stimulated insulin and glucagon secretion (GSIS/GSGS), calcium flux assays (KCl-induced depolarization), and flow cytometry.

3. Key Contributions

• Clinical Workflow Adaptation: Successfully translated an experimental progenitor platform into a workflow compatible with clinically derived, non-endocrine tissue fractions (waste streams from islet isolation).
• Prospective Enrichment Strategy: Validated CD81/CD9 as effective surface markers for prospectively enriching a population of adult pancreatic progenitors with high endocrine differentiation potential.
• Definition of IPC States: Used scRNA-seq to define the transcriptional landscape of IPCs, identifying specific progenitor markers (GREM1, FST, PTX3, CEMIP) and their transition to endocrine states.
• Functional Validation: Demonstrated that organoids derived from adult human tissue can acquire key physiological functions, including glucose-responsive hormone secretion and depolarization-induced calcium influx.

4. Key Results

A. Expansion and Morphology

• Non-endocrine fractions yielded expandable cell populations that formed adherent monolayers.
• CD81+/CD9+ sorting significantly enriched for progenitor-associated markers. Sorted cells formed dense, 3D spherical clusters (IPC clusters) upon high-density culture, whereas unsorted or CD81-/CD9- populations showed reduced efficiency in cluster formation.
• Sorted CD81+/CD9+ cells exhibited high expression of BMPR1A (33.1%) and P2RY1 (60.7%), markers associated with progenitor competency.

B. Molecular Characterization (scRNA-seq)

• Progenitor Signature: Undifferentiated IPCs and clusters were characterized by the enrichment of genes GREM1, FST, PTX3, and CEMIP.
• Differentiation Trajectory: Upon ISX9 treatment, cells transitioned from IPC/progenitor states to distinct endocrine lineages (beta, alpha, delta, and poly-endocrine).
• Lineage Alignment: Differentiated organoids aligned with reference human islet endocrine signatures in UMAP space. A "poly-endocrine" (Poly-Endo) intermediate population was identified, co-expressing hormones before resolving into monohormonal beta (INS+) and alpha (GCG+) cells.
• Gene Expression: Differentiation induced canonical transcription factors (PDX1, NKX2.2, MAFA, NKX6.1) and functional genes (INS, GCG, IAPP, SST, GCK, PCSK1).

C. Functional Assays

• Calcium Flux: ISX9-treated organoids exhibited robust, depolarization-induced Ca²⁺ influx in response to KCl, a hallmark of endocrine cell excitability. Unsorted controls were unresponsive.
• Hormone Secretion:
  • Insulin: Organoids showed significantly increased insulin secretion under high glucose (16.7 mM) compared to low glucose (1.67 mM).
  • Glucagon: Glucagon secretion was elevated under low-glucose conditions, demonstrating appropriate counter-regulatory response.
• Protein Expression: Immunofluorescence confirmed the presence of insulin-positive cells within defined 3D structures.

5. Significance and Implications

• Autologous Therapy Potential: This study establishes a proof-of-concept for generating an unlimited autologous source of islet-like cells from a patient's own pancreatic tissue (specifically the non-islet fractions discarded during TPIAT). This could bypass donor scarcity and immune rejection issues.
• Clinical Translation: The workflow is designed to be compatible with clinical islet isolation protocols, making it a viable strategy for future cell replacement therapies in Type 1 and Type 2 diabetes.
• Mechanistic Insight: The identification of CD81/CD9 as enrichment markers and the transcriptional mapping of the IPC-to-islet transition provide a roadmap for optimizing future differentiation protocols.
• Limitations & Future Work: The authors note that marker expression is influenced by culture conditions and that long-term stability and in vivo performance of these organoids require further investigation. However, the functional data (glucose responsiveness) strongly supports the therapeutic potential of this approach.

In summary, this paper provides a robust, clinically adaptable framework for converting "waste" pancreatic tissue into functional, patient-specific islet organoids, offering a promising avenue for regenerative medicine in diabetes.